Tech Company Financing Transactions
Accera Funding Round
Accera, based in Boulder, secured $35 million in funding from Inventages Venture Capital and Posco BioVentures.
Transaction Overview
Company Name
Announced On
11/12/2008
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series C
Investors
Inventages Venture Capital (Lead Investor) (Wolfgang Reichenberger)
Proceeds Purpose
Proceeds of this financing will be used to begin sales and marketing of the company's lead product, Axona(TM) (previously known as Ketasyn), which is scheduled to launch in the United States in the first quarter of 2009.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3005 Center Green Dr. 205
Boulder, CO 80301
USA
Boulder, CO 80301
USA
Phone
Website
Email Address
Overview
Accera is a clinical stage biotechnology company developing therapies for central nervous system disorders including Alzheimer's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles Stacey
Chief Financial Officer
Evan Ballantyne
Chief Medical Officer
Judy Walker
VP - Bus. Development
Ernest Wong
VP - Finance
Jerris Knaisch
VP - R & D
Samuel Henderson
Browse more venture capital transactions:
Prev: 11/12/2008: ElectraTherm venture capital transaction
Next: 11/12/2008: New Relic venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs